BMO Capital Markets Reiterates “Outperform” Rating for Pfizer (NYSE:PFE)
Related Articles
-
Leerink Partnrs Reaffirms Outperform Rating for Cartesian Therapeutics (NASDAQ:RNAC)
Leerink Partnrs reiterated their outperform rating on shares of Cartesian Therapeutics (NASDAQ:RNAC – Free Report) in a research report sent to investors on Tuesday morning, Zacks.com reports. Leerink Partnrs also issued estimates for Cartesian Therapeutics’ Q1 2024 earnings at ($1.34) EPS, Q2 2024 earnings at ($1.38) EPS, Q3 2024 earnings at ($1.27) EPS, Q4 2024 […]
-
Croda International (LON:CRDA) Earns Buy Rating from Jefferies Financial Group
Jefferies Financial Group reiterated their buy rating on shares of Croda International (LON:CRDA – Free Report) in a research report sent to investors on Wednesday, MarketBeat.com reports. The brokerage currently has a GBX 5,300 ($66.57) price target on the stock. Separately, Berenberg Bank restated a buy rating and issued a GBX 5,200 ($65.32) price target […]
-
Ashtead Group (LON:AHT) Earns “Buy” Rating from Jefferies Financial Group
Jefferies Financial Group restated their buy rating on shares of Ashtead Group (LON:AHT – Free Report) in a research report report published on Wednesday, Marketbeat.com reports. Jefferies Financial Group currently has a GBX 6,150 ($77.25) price target on the stock. A number of other equities research analysts have also recently commented on AHT. Royal Bank […]